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Guidelines for thromboprophylaxis in pregnancy are usually based upon clinical observations and expert opinion. For optimal
impact, their use must be attended by consistency in the advice given to women. In this observational study, we evaluated the
performance of a scoring system, used as a guide for clinicians administering dalteparin to pregnant women at increased risk of
venous thromboembolism. The work included 47 women treated with dalteparin prior to adoption of the scoring system and 58
women treated with dalteparin after its adoption. The indication for thromboprophylaxis was recorded in each case together with
details of the regimen employed, obstetric, and haematological outcomes. The main outcome measure was to determine whether
consistencyimprovedafteradoptionofthescoringsystem.Wealsorecordedtheoccurrenceofanynewvenousthromboembolism,
haemorrhage, the use of regional anaesthesia during labour, evidence of allergy, and thrombocytopenia. We found that use of the
scoring system improved the consistency of advice and increased the mean duration of thromboprophylaxis. None of the subjects
suﬀered venous thromboembolism after assessment using the scoring system. There was no increase in obstetric or anaesthetic
morbidity when dalteparin was given antenatally period and no evidence of heparin-induced thrombocytopenia.
1.Introduction
Venous thromboembolism (VTE) has been the commonest
noniatrogenic, direct cause of maternal death in England
and Wales for many years, reﬂecting a longstanding UK
wide pattern of disease [1, 2]. This is largely attributable to
pregnancy-related changes in clotting factors that lead to a
state of physiological hypercoagulability [3, 4]. A number
of additional factors that increase the risk of a woman
developing VTE in pregnancy have been identiﬁed however,
including a personal or family history of VTE, increased
maternal age or body weight, and the presence of a known
heritable thrombophilia [5–8].
Although an established VTE in pregnancy may be
treated successfully with therapeutic doses of heparin, pre-
vention is preferable to cure because of the high mortal-
ity and long-term morbidity associated with established
disease [9, 10]. Low-molecular-weight heparins (LMWHs)
are eﬀective thromboprophylactic agents, do not cross the
placenta, and do not appear in breast milk [11–14]. They
can be used safely in pregnancy and in breastfeeding with
no adverse fetal or neonatal eﬀects. Furthermore maternal
allergy, osteoporosis, and thrombocytopenia are rare even
after prolonged use [15–17], while epidural and spinal
anaesthesiaarealsothoughttobesafeforlabouranddelivery
if at least 12 hours have elapsed since the last administration
time of the drug [18]. Because of their eﬃcacy and good
safety proﬁle, the use of low molecular weight heparins for
thromboprophylaxis in pregnancy has increased greatly in
recent years.
Am e a s u r e da p p r o a c ht ot h eu s eo fL M W Hi sn e v e r -
theless essential because although side eﬀects are rare, their
increased use in pregnancy is likely to be associated with
an increase in the absolute numbers of adverse events en-
countered. In addition, self-administration of parenteral
agentsseemsoneroustosomewomenandinlabour,regional2 Thrombosis
Table 1: Anticoagulation recommendations published in the BJOG, August 1999 [21].
Very high risk
Previous VTE while taking anticoagulants
Thromboprophylaxis with dose adjusted for anti-Xa activity throughout pregnancy and
for 12 weeks postpartum. VTE in the current pregnancy
Antithrombin deﬁciency
High risk
Previous VTE while not on anticoagulants
Fixed dose of LMWH from 24 weeks, earlier if additional risk factors for VTE. With
previous pregnancy associated VTE, start 4–6 weeks ahead of gestation of the previous
event and continue for 12 weeks postpartum.
Protein C deﬁciency and FMH
Homozygous Factor V Leiden
Homozygous prothrombin gene mutation
Combined thrombophilias
Moderate risk
Heterozygous factor V Leiden
Postpartum LMWH prophylaxis for 6 weeks. Heterozygous prothrombin gene mutation
Heterozygous protein S deﬁciency
FMH alone
Relatively low risk
Heterozygous Factor V Leiden with no FMH Monitor for additional risks.
Heterozygous PT gene mutation with no FMH
VTE: venous thromboembolism, LMWH: low molecular weight heparin, FMH: family history of VTE.
anaesthesia may occasionally be withheld or delayed because
LMWH has been administered in the preceding 12 hours.
Bearing these issues in mind, we constructed a novel Throm-
boprophylaxis Scoring System in order to identify women at
high risk of VTE in pregnancy, to guide the timing of onset
and duration of therapy, and thereby to promote consistency
in clinical practice. In the present study we compare the
management of women with a perceived high risk of VTE
before and after introduction of the scoring system, while
documenting pregnancy outcomes in the two groups using
a number of obstetric and haematological indices. We also
comment upon the content of the scoring system in relation
to recommendations subsequently published by the Scottish
Intercollegiate Guidelines Network (SIGN, 2002) and by the
Royal College of Obstetricians and Gynaecologists (RCOG,
2009) [19, 20].
2. Patientsand Methods
2.1.ConstructionoftheScoringSystem. Thromboprophylaxis
with the LMWH dalteparin was introduced into clinical
practice in the Royal Victoria Inﬁrmary, Newcastle upon
Tyne, in 1996. Between January 1997 and April 2001, women
perceived by the GP, Community Midwife or Obstetrician
to be at high risk of VTE in pregnancy were referred to an
Obstetric Medicine Clinic for specialist advice. Here, a full
medical history was taken and a thrombophilia screen was
performedif a personalor familyhistory of VTE waselicited.
The need for treatment with dalteparin, the gestation for
initiation of the drug, and the total duration of prophylaxis
was then gauged by a consultant physician and a consultant
obstetrician on an individualised basis. No speciﬁc local
guidelines were in place to promote referral to the clinic or
to guide timing and duration of therapy, but an established
principle was that when prophylaxis was being oﬀered on the
grounds of a VTE in a previous pregnancy, treatment should
commence four weeks prior to the gestation of that event.
In April 2001, a multidisciplinary group of physicians,
haematologists, and obstetricians was convened to provide
local guidance for thromboprophylaxis in pregnancy. This
group came to a consensus opinion about the relative
importance of individual risk factors for the development
of VTE in pregnancy by drawing upon available evidence
and personal experience. In particular, reference was made
to articles published in the British Journal of Obstetrics and
Gynaecology in 1999 and the British Journal of Haematology
in 2001 [21, 22], the latter having been endorsed by the
British Society for Haematology. Summaries of these papers
are presented as Tables 1 and 2.
On these bases, a Thromboprophylaxis Scoring System
was compiled in which individual risk factors were allocated
aw e i g h t e ds c o r e( Table 3). It was agreed that the total score
allocated to each woman referred for review at the Obstetric
Medicine Clinic thereafter would be used to determine the
need for prophylaxis and the gestation at which prophylaxis
should be commenced. After treatment was started, the aim
was to continue until 6 weeks postpartum in all cases. In
this way, it was hoped that a uniform high standard of
evidence-based care could be provided to all women referred
to the clinic. The risk factors identiﬁed on the scoring system
were also promoted as a guide for referral to the clinic after
being made available to GPs, community midwives, and
other consultant obstetricians in the hospital.
2.2.DatabaseConstruction. Adatabasewasconstructedcon-
taining the details of all women referred for specialist adviceThrombosis 3
Table 2: Anticoagulation recommendations published in the British Journal of Haematology, January 2001 [22].
High risk
On long-term anticoagulants
Pregnancy-long thromboprophylaxis. Consider using 75 anti Xa units/kg 12
hourly. Continue treatment for 6 weeks postpartum. Type 1 antithrombin deﬁciency
Type 2 reactive site antithrombin defect
Moderate risk
Previous precipitated VTE plus thrombophilic defect
Consider antenatal thromboprophylaxis with 4000 to 5000 anti-Xa units of
LMWH once daily, starting in either the ﬁrst or second trimester and
continuing for 6 weeks postpartum.
Previous unprecipitated VTE
Homozygous factor V Leiden plus FMH
Homozygous prothrombin gene mutation plus FMH
Heterozygous protein C deﬁciency plus FMH
Combination of thrombophilias
Slightly increased risk
Heterozygous protein S plus FMH
Consider thromboprophylaxis after delivery for 6 weeks, particularly if other
risk factors are present such as increased maternal age.
Heterozygous factor V Leiden plus FMH
Heterozygous prothrombin gene mutation plus FMH
Previous precipitated VTE, no thrombophilia
VTE = venous thromboembolism, LMWH = low molecular weight heparin, FMH = family medical history of VTE.
Table 3: The Thromboprophylaxis Scoring System.
Risk factor Score
Age >35 years 0.5
Weight >120kg 0.5
VTE in two or more ﬁrst or second degree relatives 0.5
Previous nonobstetric provoked VTE 1.0
Previous nonobstetric unprovoked VTE 2.0
Previous VTE on the combined oral contraceptive pill 2.0
Previous obstetric VTE∗ 2.0
Antithrombin deﬁciency (use anticoagulant dose adjusted
for weight) 3.0
Protein C deﬁciency∗∗ 1.5
Protein S deﬁciency∗∗ 1.0
Factor V Leiden∗∗ 1.0
Prothrombin gene mutation (G20210A)∗∗ 1.0
Antiphospholipid antibodies∗∗∗ 1.0
Total Score
Total score/Thromboprophylaxis: Under 1.0: conservative management,
lifestyle advice; 1.0–1.5: from delivery until 6 weeks postpartum; 2.0–2.5:
from 28 weeks until 6 weeks postpartum; 3.0 or more: from diagnosis
of pregnancy until 6 weeks postpartum; ∗begin therapy at least 4 weeks
before the gestation of the previous VTE; ∗∗pregnancy long therapy for
homozygous conditions; ∗∗∗individualised care for recurrent pregnancy
loss.
VTE: venous thromboembolism. ’Precipitated’ refers to VTE following an
identiﬁable cause such as trauma, surgery, immobilisation, air travel or
malignant disease.
to the Obstetric Medicine Clinic from January 1997, who
were deemed to be at an increased risk of VTE and who
were therefore given dalteparin. Two groups of women were
entered onto this database, the ﬁrst group consisting of
women treated with dalteparin prior to the introduction
of the scoring system (1997–2001) and the second group
consisting of women prescribed dalteparin after its introduc-
tion (2001–2003). The information recorded on the database
included maternal age and weight at booking. Previous
personal obstetric, medical, and surgical histories were also
noted together with the use of other drugs, known allergies,
and the presence of any relevant family history of VTE. The
stated indication for thromboprophylaxis was then recorded,
together with the gestation at which dalteparin was com-
menced, the dose administered, and the duration of therapy.
Side eﬀects of therapy were also documented, including
evidence of local or systemic allergic reactions. Platelet
counts were determined 7 days after therapy commenced
then monthly thereafter. Each patient’s lowest count was
recorded on the database regardless of gestation. In addition,
the results of thrombophilia screening performed before,
during or after pregnancy, were recorded. Finally, obstetric
noteswereexaminedandarecordwasmadeofeachwoman’s
antenatal, intrapartum, and postnatal progress, including
details of antepartum haemorrhage, gestation, and mode of
delivery, estimated blood loss at delivery, blood transfusion,
and the use of regional analgesia in labour or at caesarean
section.
2.3. Exclusions. The Thromboprophylaxis Scoring System
was constructed to assist in the care of women identiﬁed
antenatally to be at an increased risk of a pregnancy-
related VTE. In the period of study, low-molecular-weight
heparin was also prescribed for women having an elective or
emergency caesarean section but who had no additional risk
factors for VTE, for a period of 1 to 5 days, with an increase
in the duration of prophylaxis being advocated in the more
recent years. In addition, women with a BMI over 35kg/m2
and woman admitted to the antenatal and postnatal wards
for in-patient care are also now risk assessed for VTE but this4 Thrombosis
wasnotstandardpracticeduringthestudyperiod.Datafrom
these groups of patients have not been included in this paper.
2.4. Statistical Analyses. Student’s t-test was used to compare
the mean values of continuous variables in the two groups
while variance in the time of commencement of therapy was
examined with reference to tables of F. For categorical data,
2 × 2a n d2× k contingency tables were constructed then χ2
analyses was performed.
3. Results
In the 52 months prior to introduction of the scoring system,
47 women commenced dalteparin therapy for thrombo-
prophylaxis after referral to the Obstetric Medicine Clinic.
Over this time course, 18542 women gave birth in the
unit. In the 32 months after its introduction, a further
58 women were treated with dalteparin after referral to
the clinic, over which time 13975 women gave birth in
the unit. Over the whole study period, 91 women received
both antenatal and postnatal thromboprophylaxis while the
remaining 14 received postnatal prophylaxis alone. The
proportion of women attending the hospital who were given
thromboprophylaxis therefore increased after introduction
of the scoring system (P<0.001). The mean age [SD] of
womengiventhromboprophylaxisbeforeintroductionofthe
scoring system was 28.9 [5.6] years compared to 29.9 [5.5]
years after its introduction, representing no change (P>
0.05). The mean booking weight [SD] was 74.3 [17.0] kg
before the scoring system was introduced compared to 78.8
[16.3] kg after, again representing no change (P>0.05).
3.1. Previous History of Venous Thrombosis While Taking
the Combined Oral Contraceptive Pill. Prior to introduction
of the scoring system, 14 women were identiﬁed who
had developed a VTE while taking the combined oral
contraceptive pill. These included 4 women with a below
knee thrombosis, 9 with a thrombosis at any venous site
above the knee, and 1 woman with a pulmonary embolus.
Only 2 of the group had a family history of VTE. Dalteparin
prophylaxis was commenced at a gestation varying between
18 weeks gestation and full term, then continued until 4 to 6
weeks postpartum. After introduction of the scoring system,
a further 19 women were identiﬁed with a history of pill-
related VTE, including 7 with a below knee thrombosis, 10
with thrombosis above the knee, and 2 with a pulmonary
embolus. Three had a family history of VTE. Thrombopro-
phylaxis was commenced between 11 and 30 weeks gestation
and continued until 6 weeks postpartum in each case.
The gestation at commencement of therapy was com-
pared between the two groups in order to determine whether
the consistency of advice changed after introduction of the
scoring system. Women were only included in this analysis if
they had suﬀered an above knee thrombosis or a pulmonary
emboluswhiletakingthepill,buthadnootheridentiﬁedrisk
factors for VTE. This was to ensure like-for-like comparison
between the two groups. In these circumstances, before
introduction of the scoring system, thromboprophylaxis
commenced between 18 and 40 weeks gestation with a mean
starting point [SD] of 31.1 [7.7] weeks of gestation (n =
9). After the scoring system was introduced, therapy was
commenced between 27 and 29 weeks of gestation, with a
mean [SD] of 28.8 [0.47] weeks (n = 10). Although the
mean gestation at which prophylaxis with dalteparin was
commenced was unchanged by introduction of the scoring
system (P>0.05), variance in the timing of onset of therapy
was signiﬁcantly reduced (P<0.001).
3.2. Previous History of Venous Thrombosis in Pregnancy.
Between January 1997 and April 2001, 22 women were
identiﬁed who gave a history of venous thrombosis in a
previous pregnancy, including 3 whose presentation had
been with thrombosis below the knee, 12 with thrombosis
above the knee, and a further 7 presenting with pulmonary
embolus. All of these events took place in the second or third
trimester of pregnancy. In each case, prophylactic dalteparin
was prescribed, commencing between 1 and 9 weeks prior
to the gestation at which the previous thrombosis had been
identiﬁed. Between May 2001 and December 2003, a further
23 women were identiﬁed who gave a history of venous
thrombosisinapreviouspregnancy,including3womenwith
a history of below knee thrombosis, 15 with a previous above
knee thrombosis, and 5 women with a previous pregnancy
related pulmonary embolus. Nineteen of these events took
place in the second and third trimesters and four took place
in the puerperium. In each case, a prophylactic dose of dal-
teparin was given, commencing between 4 and 22 weeks
prior to the gestation of occurrence of the previous VTE, but
not later than 30 weeks gestation in any single case.
In general, earlier anticoagulation was advised after in-
troduction of the scoring system (26.7 [6.4] weeks versus
20.7 [7.7] weeks, P<0.01). Variance analysis could not be
employed to examine the consistency of advice given in this
category due to the clinical heterogeneity encountered. Only
12/22 women commenced dalteparin at least 4 weeks prior
to the gestation of the previous VTE before introduction
of the scoring system however, compared to 23/23 after its
introduction. This represents a signiﬁcant change in practice
(P<0.001), suggesting greater consistency in clinical de-
cision making.
3.3. Previous History of Unprovoked and Provoked Venous
Thrombosis Outside of Pregnancy. Before introduction of the
scoring system, 6 women were identiﬁed who had previously
suﬀered a nonobstetric, unprecipitated VTE, including 2
women with a below knee VTE, and 4 with a pulmonary
embolus. Two of the women who had previously had a
pulmonary embolus also had a family history of VTE.
Dalteparin was commenced between 18 and 38 weeks ges-
tation then continued uniformly until 6 weeks postpartum.
After introduction of the scoring system, another 7 women
were identiﬁed with a previous unprovoked VTE including
1 with a below knee thrombosis, 2 with an above knee
thrombosis, and 4 with a pulmonary embolus. Two of these
had a family history of VTE. The timing of commencement
of thromboprophylaxis varied between 14 and 28 weeksThrombosis 5
gestation after introduction of the scoring system and con-
tinued until 6 weeks postpartum in each case.
To examine consistency of advice, the timing of onset
of therapy was analysed in 4 women treated before intro-
duction of the scoring system and 5 women treated after its
introduction, none of whom had additional risk factors for
VTE. The gestation [SD] at onset of treatment was 28.0 [9.3]
weeks versus 28.0 [0.71] weeks, respectively, demonstrating
greater consistency after introduction of the scoring system
(P<0.001).
Over the whole period of study, 5 women received a six-
week course of postpartum thromboprophylaxis on the basis
of a previous provoked VTE. These included three women
with a history of lower limb thrombosis following fracture
of the femur and two women with a history of lower limb
thrombosis following pelvic fracture. Although the numbers
treated in this group were too small to allow meaningful
statistical analysis, no clear change in clinical practice was
noted after introduction of the scoring system.
3.4.OtherIndicationsforThromboprophylaxis. Threewomen
received dalteparin on the basis of a history of VTE in at least
two ﬁrst- or second-degree relatives before introduction of
thescoringsystem.Eachhadadditionalriskfactors;twowere
heterozygous for Factor V Leiden, while the third recorded
a booking weight of 124kg and was 36 years of age. In
each case, prophylaxis was commenced between 32 and 40
weeks of gestation and was continued for 6 weeks into the
puerperium.
After introduction of the scoring system, 6 women with a
strong family history of VTE received thromboprophylaxis.
Three were heterozygous for Factor V Leiden, one had
protein S deﬁciency, one had a booking weight of 135kg and
the ﬁnal case was of a woman who was 41 years of age and
had a booking weight of 102kg.
In general, although the groups were heterogeneous
in nature, the mean gestation [SD] at commencement of
therapy was unchanged after introduction of the scoring
system (37.3 [4.6] weeks versus 37.0 [6.0] weeks, P>0.05).
All women in this category received prophylactic dalteparin
f r o md e l i v e r yu n t i l6w e e k sp o s t p a r t u m .
3.5. Retrospective Application of the Thromboprophylaxis
Scoring System. For each of the 47 women given thrombo-
prophylaxisbeforeintroductionofthescoringsystem,ascore
was calculated retrospectively by relating each individual’s
risks to the scoring system table. The diﬀerence between
actual timing of onset of therapy and the timing that would
have been suggested with reference to the scoring system
was then calculated. Earlier onset of therapy would have
been advised in 30 cases, ranging from 1 to 28 weeks of
additional heparinisation. Later onset of therapy would have
b e e na d v i s e di n1 0c a s e s ,r a n g i n gf r o m2t o1 6w e e k sl e s s
heparinisation.Anidenticaltimingofonsetoftherapywould
have been advised in the remaining 7 cases. In general, the
mean onset of timing of therapy would have been reduced
from 29.7 [7.4] weeks to 24.9 [8.5] weeks, representing a
signiﬁcantly earlier onset of therapy (P<0.01).
Table 4: Mode of delivery and estimated blood loss.
SVD IVD CS
Antenatal and
postnatal
dalteparin
EBL [SD]mL 243 [102] 423 [186] 597 [292]
n 57 19 15
Postnatal
dalteparin alone
EBL [SD]mL 290 [263] 365 [42] 355 [132]
n 554
P 0.20 0.25 0.22
EBL: estimated blood loss; SVD: spontaneous vaginal delivery; IVD:
instrumental vaginal delivery, incorporating all ventouse and forceps births;
CS: caesarean sections, incorporating elective and emergency procedures; n:
number of women in each group.
3.6. Occurrence of New Thromboses. None of the women
in the present study suﬀered a VTE in pregnancy or the
puerperium after assessment in the Obstetric Medicine Clin-
ic, before or after introduction of the scoring system.
3.7. Analgesia. Of the 91 women given antenatal thrombo-
prophylaxis, 85 laboured before delivery and 39 of these
had an epidural sited for analgesia. Of the 14 women
receiving exclusively postpartum thromboprophylaxis, 12
laboured before delivery and of these, 6 received an epidural
in labour. In each case, at least twelve hours had elapsed
since administration of dalteparin and no neurological or
haemorrhagic complications were encountered. The use of
antenatal thromboprophylaxis therefore did not mitigate
against the use of epidural for analgesia in labour (P>0.05).
3.8. Mode of Delivery. The mode of delivery for women
in the study is shown in Table 4.W o m e nw h or e c e i v e d
antenatal thromboprophylaxis were at neither an increased
nor a decreased risk of instrumental vaginal or caesarean
delivery compared to women who received postpartum
thromboprophylaxis alone (P>0.05).
3.9. Obstetric Haemorrhage. Between 1997 and 2003, 4/91
women who received antenatal prophylaxis with dalteparin
were admitted to hospital because of antepartum haem-
orrhage. Three women suﬀered unexplained spotting of
blood from the vagina in the third trimester that settled
spontaneously, while one woman experienced a major
placental abruption requiring emergency caesarean section
at full term. Of the 14 women given exclusively postpartum
prophylaxis, only one experienced a signiﬁcant antepartum
haemorrhage. In this case, the patient developed severe
pre-eclampsia then suﬀered a placental abruption at 30
weeks of gestation, requiring delivery by caesarean section.
Dalteparin therapy was given for 6 weeks after delivery as
previously planned. The use of dalteparin before delivery
was not associated with a change in the rate of antepartum
haemorrhage (P>0.05).6 Thrombosis
Table 5: Results of thrombophilia screening in women receiving dalteparin during or after pregnancy.
Indication for prophylaxis APA AT PC PS FVL PT unscreened
previous VTE on COCP 0 0 0 1 6 1 3
previous VTE in pregnancy 3 0 1 1 3 3 0
previous unprovoked VTE 0 0 0 0 0 1 0
previous provoked VTE 0 0 0 0 0 0 0
other indications 0 0 0 1 5 0 0
VTE: venous thromboemboloism; COCP: combined oral contraceptive pill; APA: antiphospholipid antibodies; AT: antithrombin deﬁciency (untyped); PC:
Protein C deﬁciency; PS: Protein S deﬁciency; FVL: heterozygous Factor V Leiden; PT: heterozygous prothrombin gene G20210A mutation. All patients were
screened after introduction of the scoring system.
The use of antenatal dalteparin did not alter the mean
estimated blood loss at spontaneous vaginal, instrumen-
tal, or caesarean delivery (Table 4). One woman receiving
exclusively postnatal thromboprophylaxis required blood
transfusion after giving birth by caesarean section while
ﬁve women who had been given antenatal dalteparin were
transfused. These included four who underwent emergency
caesarean section for obstetric indications and one woman
with a prolonged second stage of labour who was delivered
by forceps. Despite these observations, the use of blood
transfusion for women given antenatal thromboprophylaxis
was not increased to a statistically signiﬁcant extent (Fisher’s
Exact Test, P = 0.89).
3.10.Allergy. Throughouttheperiod of studydalteparin was
well tolerated although three women developed itch and a
localised macular rash shortly after commencing therapy. In
each case, dalteparin was replaced by tinzaparin, resulting
in a rapid and complete resolution of symptoms. No other
allergic reactions were noted.
3.11. Thrombocytopenia. Fourteen women receiving antena-
tal dalteparin recorded a platelet count below 150 × 109/L
during the study period but only three recorded a count
below 100 × 109/L, with minimum values of 98, 88, and
72 × 109/L, respectively. In each of these cases there was
clear evidence of pre-eclampsia. The fall in platelet count
led to a temporary discontinuation of therapy but dalteparin
wasrecommencedpostpartumandthereafter,plateletcounts
recovered despite ongoing use of the drug.
3.12. Thrombophilia Screening. The thrombophilia screen
included functional chromogenic assays for antithrombin,
Protein C and Protein S. Activated Protein C resistance was
assessed with molecular conﬁrmation of Factor V Leiden
when indicated. Prothrombin gene G20210A identiﬁcation
was also undertaken together with lupus anticoagulant
and anticardiolipin antibody status deﬁnition. Screening
was carried out either before or during pregnancy, before
dalteparinwascommenced.LowProteinCorProteinSlevels
identiﬁed during pregnancy were conﬁrmed by repeat assay
several weeks after stopping treatment. An array of heritable
thrombophilias was identiﬁed (Table 5).
Prior to introduction of the scoring system, 39 of
the 47 women with a personal or family history of VTE
were screened for heritable thrombophilias, compared to
all 58 women given dalteparin after its introduction. This
represents a signiﬁcant increase in the rate of screening (P<
0.01).
4. Discussion
The authors of a 2002 Cochrane Review entitled Prophy-
laxis for Venous Thromboembolic Disease in Pregnancy
and the Early Postnatal Period stated that there was
insuﬃcient evidence available upon which to base ﬁrm
recommendations for thromboprophylaxis in pregnancy
[23]. Robust research was called for to inform clinical
practice, mirroring the position taken a number of years
earlier by similar authors [24]. With evidence of signiﬁcant
morbidity and mortality arising from VTE in pregnancy
however, including case reports amassed through over 50
years of Conﬁdential Enquiries reports, SIGN issued ﬁrm
guidance for thromboprophylaxis in pregnancy in 2002
[19], necessarily basing their recommendations largely upon
expert opinion. Here, it was suggested that women with
unprovoked, pill-related or pregnancy-related previous VTE
should be oﬀered prophylaxis with a low-molecular-weight
heparin as early in pregnancy as possible and that therapy
should continue into the puerperium. This move towards
early anticoagulation was endorsed by the RCOG in their
2004 Green-top Guideline document, “Thromboprophylaxis
During Pregnancy, Labour and After Vaginal Delivery” [25],
now superseded by the 2009 Green-top Guideline “Reducing
the risk of thrombosis and embolism during pregnancy
and the puerperium” [20]. Audit data collected through the
Conﬁdential Enquiries system in coming years will provide
some measure of the success or failure of these guidelines,
particularly in the face of current trends towards an increase
in maternal age, maternal obesity, and operative delivery
currently being experienced in the UK.
The SIGN and RCOG Guidelines make a limited attempt
to assess an individual’s risk for VTE and to tailor the
therapeutic regimen oﬀered accordingly. This simpliﬁed
approach is justiﬁed if (1) the risk of a VTE arising at
any point in time in a high-risk population remains similar
throughout each trimester of pregnancy, (2) prophylaxis
with low-molecular-weight heparin is eﬀective in preventing
VTE throughout pregnancy, (3) potential adverse events
associated with the prolonged use of prophylactic low mo-
lecular weight heparin are outweighed by the beneﬁts ofThrombosis 7
therapy, and (4) the simplicity of advice oﬀered lends itself
to consistency in clinical practice. In most respects, these
criteria have already been met. For example, although some
reports suggest that the absolute risk of new or recurrent
VTE during pregnancy is low [26, 27], one large cohort
study bears out the principle that the risk of recurrent
VTE is nevertheless increased throughout pregnancy when
thromboprophylaxis is withheld, with a particularly high-
risk manifest postpartum [28]. Furthermore, there have
been several case series reported in which the prolonged
use of low-molecular-weight heparin in pregnancy appeared
to be eﬀective in preventing thrombosis while causing few
clinically signiﬁcant side eﬀects. It remains to be shown
however that use of the SIGN or RCOG Guidelines promotes
consistency in clinical practice. This is an important goal if
their full potential beneﬁt is to be realised.
Introduction of the Thromboprophylaxis Scoring System
presented in this paper brought about a marked improve-
ment in the consistency of the clinical management of wom-
en at increased risk of VTE in pregnancy. A theoretical
advantage of the scoring system over the SIGN and RCOG
Guidelines is that it has achieved this consistency while re-
taining a highly individualised assessment of a woman’s VTE
riskinthefaceofmultipleriskfactorsforthromboembolism.
Whether or not this delivers a clinical advantage remains
unproven. To this end, the scoring system could now be
used in the context of a randomised controlled trial in
the manner recommended in the Cochrane Review of 2004
[24]. Alternatively, if the pragmatic opinion of authors of
the SIGN and RCOG documents is accepted together with
the evidence that the Thromboprophylaxis Scoring System
improves consistency of approach, the recommendations
held within the system might now be altered to comply with
therecommendationsoftheseguidelines.Speciﬁcally,ascore
of 2.0 could trigger prophylaxis with a standard, once daily
dose of LMWH throughout pregnancy while a score of 3.0 or
more could for example trigger weight adjusted prophylaxis
with concomitant anti-Xa monitoring.
In summary, use of the Thromboprophylaxis Scoring
System presented in this paper improved consistency of
approach when advice was being given to women with a
high risk of VTE in pregnancy. Although speciﬁc elements
of the advice given would require modiﬁcation to comply
withcurrentSIGNandRCOGGuidelines,thescoringsystem
remains a useful tool in clinical practice and could be
employed in further large-scale research work examining the
eﬃcacy of diﬀerent thromboprophylaxis regimens in high-
risk pregnancies.
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